Abstract
For 30 years nature has provided a plethora of natural products with potential meaningful anti-cancer activity. Fusarochromanone (FC101a) is a small molecule fungal metabolite exhibiting potent in-vitro growth inhibitory effects and is capable of inducing apoptosis, suppressing angiogenesis and tumorigenesis, and inhibiting endothelial cell growth in multiple cancer cell lines. Despite all we know regarding FC101a, the mechanism of action and molecular target(s) of this compound have remained an enigma. Furthermore, modest in-vivo activity has been documented and requires addressing. Early stage pharmacokinetics (PK) assessment is vital to successful drug development. Herein, we aimed to use in-silico assays to i) characterize an in-depth ADMET profile of FC101a and ii) to probe for possible therapeutic targets. Two-dimensional SDF files of FC101a and 13 analogs were introduced into ADMET Predictor Version 7.1 that parses the structures in order to calculate molecular descriptors, which are used to estimate ADMET properties. Calculated ADMET values were analyzed and subjected to multiple drug-like indices, delivering a PK profile of each analog. To probe for possible targets, a total of 49 proteins were introduced into SYBYL-X ...Continue Reading
References
Aug 1, 1994·The American Journal of Physiology·M B LandeM L Zeidel
Jul 1, 1997·The Journal of Pharmacy and Pharmacology·H LennernäsG L Amidon
Apr 4, 2000·Journal of Combinatorial Chemistry·A K GhoseJ J Wendoloski
May 18, 2001·Journal of Pharmaceutical Sciences·Y H ZhaoD Boutina
May 31, 2002·Journal of Medicinal Chemistry·Daniel F VeberKenneth D Kopple
Mar 4, 2003·Nature Reviews. Drug Discovery·Han van de Waterbeemd, Eric Gifford
Aug 4, 2004·Clinical Pharmacology and Therapeutics·Steven G SimonsonDennis W Schneck
Jun 28, 2005·Journal of Neuropathology and Experimental Neurology·Hiroko Ohgaki, Paul Kleihues
Dec 7, 2007·Chemical Research in Toxicology·F Peter Guengerich
Jan 29, 2008·Current Pharmaceutical Design·S A ShaikhB Jayaram
Feb 22, 2008·Current Cancer Drug Targets·Ahmad R SafaChing-Huang Wu
May 7, 2009·Proceedings of the National Academy of Sciences of the United States of America·Jong W YuYigong Shi
Oct 16, 2009·Journal of Medicinal Chemistry·Frank LoveringChristine Humblet
Nov 26, 2009·The International Journal of Biochemistry & Cell Biology·Marina BagnoliDelia Mezzanzanica
Apr 29, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Makiko KusamaYuichi Sugiyama
Apr 30, 2010·Journal of Molecular Graphics & Modelling·Santiago VilarStefano Costanzi
Feb 10, 2012·Journal of Natural Products·David J Newman, Gordon M Cragg
Jul 10, 2014·The AAPS Journal·Chelsea M HoseyLeslie Z Benet
Jul 16, 2014·International Journal of Molecular Medicine·Elahe MahdavianQuincy A Quick
Sep 5, 2014·BMC Research Notes·Elahe MahdavianJohn L Clifford
Jan 1, 2013·In Silico Pharmacology·Fidele Ntie-KangSimon M N Efange
Citations
Sep 29, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ming HongYibin Feng
Feb 15, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ming HongWeiwei Xing
Oct 9, 2019·Journal of Food and Drug Analysis·Rania El-ShahenyMahmoud El-Maghrabey
Aug 8, 2020·Rapid Communications in Mass Spectrometry : RCM·Shristy S TiwariM V N Kumar Talluri
Jan 10, 2019·Evidence-based Complementary and Alternative Medicine : ECAM·Jie LiChanggang Sun
Jan 5, 2021·Journal of King Saud University. Science·Ranjan K MohapatraSaud I Al-Resayes
Jan 17, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ahmad Husein AlkaffUsman Sumo Friend Tambunan
Jul 13, 2021·Frontiers in Endocrinology·Harish JoshiIranna Kotturshetti
Jul 3, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Vanessa Loaiza-CanoMarlen Martinez-Gutierrez
Oct 22, 2020·Journal of Agricultural and Food Chemistry·Guan PengweiJun Li
Aug 29, 2019·ACS Omega·Caroline Manto Chagas, Laleh Alisaraie